Bear Bile Macromolecular Extract for HCV Protease Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hepatitis C, particularly those targeting the HCV NS3/4A protease, have limited efficacy and are associated with significant side effects, necessitating the development of a more effective and safer anti-HCV drug.
Innovation Solution
A bear bile macromolecular extract is prepared using a method involving centrifugation and separation through a cross-linked dextran SEPHADEX®-G100 column to inhibit HCV NS3/4A protease, which is then formulated into various pharmaceutical forms to enhance its therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleoside analogues and ribavirin are used to treat Hepatitis C, then the replication of hepatitis C virus is blocked, but the treatment has significant side effects and high cost
Solution Approach 1:
The patent extracts and isolates the active anti-HCV components from bear bile through systematic separation processes including precipitation, ultrafiltration, and chromatography. This extraction principle allows obtaining a concentrated macromolecular extract containing the therapeutic active substances while removing unwanted components, thereby maintaining efficacy while reducing side effects and cost.
Solution Approach 2:
The patent employs parameter changes in the form of systematic fractionation processes (precipitation at different concentrations, ultrafiltration with different molecular weight cutoffs, chromatography with varying elution conditions) to separate and purify the active macromolecular components from bear bile. These parameter adjustments enable isolation of the therapeutic fraction with optimized anti-HCV activity and reduced toxicity.
2Reliability
If interferon and ribavirin are combined for Hepatitis C treatment, then sustained virologic response rate improves, but the treatment duration is extended and cost increases
Solution Approach 1:
The patent extracts the active anti-HCV macromolecular substances from bear bile through systematic separation processes. This extraction provides a concentrated therapeutic fraction that may achieve similar or superior virologic response rates with potentially shorter treatment duration, addressing the time loss issue associated with conventional long-term interferon and ribavirin therapy.
3Reliability
If nucleoside analogues are used to treat Hepatitis C, then viral replication is inhibited, but the treatment cost is too high
Solution Approach 1:
The patent extracts active anti-HCV components from bear bile through precipitation, ultrafiltration, and chromatography processes. This extraction provides a natural source of therapeutic macromolecules that may serve as cost-effective alternatives to expensive synthetic nucleoside analogues while maintaining viral replication inhibition efficacy.
Solution Approach 2:
The patent utilizes bear bile, a natural biological resource, as a source of anti-HCV macromolecules. This natural extract may provide a more economical treatment option compared to expensive proprietary nucleoside analogue medications, addressing the cost issue while maintaining therapeutic effectiveness.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bear bile macromolecular extract demonstrates high inhibitory activity against HCV NS3/4A protease with minimal side effects, offering a promising treatment option for Hepatitis C that could prevent chronic infection, cirrhosis, and liver cancer, potentially benefiting a significant portion of infected individuals worldwide.
Implementation Method 1
centrifuge the solution by a molecular sieve filter membrane with molecular weight cut-off of 100,000 at the centrifugal force of 4000×g for 10-60 minutes
Implementation Method 2
centrifuge the solution by a molecular sieve filter membrane with molecular weight cut-off of 100,000 at the centrifugal force of 4000×g
Implementation Method 3
add the solution to a pretreated cross-linked dextran SEPHADEX®-G100 column, separate the solution by using water or buffer as the elution solvent
Implementation Method 4
collect the eluent with absorption at 280 nm, freeze-dry to obtain the bear bile macromolecular extract
Data Source
AI summary
A bear bile macromolecular extract with anti-HCV virus function is disclosed. A preparation method comprises the following steps of: taking fresh bear bile or dissolving bear bile powder with water, centrifuging it by a molecular sieve filter membrane with molecular weight cut-off of 100,000 or an ultrafiltration membrane, filtering to obtain sediment, dissolving the sediment with water, adding the solution to sephadex column, separating the solution by using water or buffer as elution solvent, and freeze-drying the eluent to obtain the bear bile macromolecular extract. Experiments show that the bear bile macromolecular extract has anti-HCV virus function and can be used for treating hepatitis C.